

Elizabeth Garrett-Mayer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9435721/publications.pdf>

Version: 2024-02-01

207
papers

12,963
citations

30070

54
h-index

24982

109
g-index

215
all docs

215
docs citations

215
times ranked

18704
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncology Practice, 2022, 18, e426-e441.	2.9	16
2	Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot. Clinical Pharmacology and Therapeutics, 2022, 111, 444-454.	4.7	12
3	Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology, 2022, 40, 106-106.	1.6	1
4	Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology, 2022, 40, 107-107.	1.6	5
5	Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. JCO Oncology Practice, 2022, , OP2100455.	2.9	0
6	Clinical Evidence Generation During a Pandemic. Cancer Journal (Sudbury, Mass), 2022, 28, 151-156.	2.0	2
7	Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts. JCO Precision Oncology, 2022, 6, e2100390.	3.0	2
8	Relationship Between Participation in ASCO's Quality Oncology Practice Initiative Program and American Board of Internal Medicine's Maintenance of Certification Program. JCO Oncology Practice, 2022, , OP2100777.	2.9	0
9	Defining comprehensive biomarker-related testing and treatment practices for advanced non-small cell lung cancer: Results of a survey of U.S. oncologists. Cancer Medicine, 2022, 11, 530-538.	2.8	28
10	Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient survey. Cancer, 2022, , .	4.1	9
11	Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative. JCO Oncology Practice, 2022, , OP2100807.	2.9	0
12	Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. Journal of Clinical Oncology, 2022, 40, 2163-2171.	1.6	68
13	Sexual Orientation and Gender Identity Data Collection in Oncology Practice: Findings of an ASCO Survey. JCO Oncology Practice, 2022, 18, e1297-e1305.	2.9	25
14	Associations between biomarker testing and characteristics of patients with metastatic non-small cell lung cancer (mNSCLC): An analysis of CancerLinQ Discovery (CLQD) data.. Journal of Clinical Oncology, 2022, 40, 9127-9127.	1.6	0
15	Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.. Journal of Clinical Oncology, 2022, 40, 6530-6530.	1.6	2
16	Presentation, management, and outcome of COVID-19 among patients with cancer in the Middle East and North Africa (MENA) region.. Journal of Clinical Oncology, 2022, 40, e18797-e18797.	1.6	0
17	Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.. Journal of Clinical Oncology, 2022, 40, 3008-3008.	1.6	7
18	COVID-19 vaccine uptake in patients with cancer and Sars-Cov-2 infection in 2020: Results from the ASCO registry.. Journal of Clinical Oncology, 2022, 40, e18713-e18713.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. Journal of Clinical Oncology, 2022, 40, 3114-3114.	1.6	2
20	Oncologistsâ€™ perspectives on individualizing dose selection for patients with metastatic cancer.. Journal of Clinical Oncology, 2022, 40, 1531-1531.	1.6	0
21	Breakthrough COVID-19 cases and hospitalization risk: ASCO COVID-19 registry.. Journal of Clinical Oncology, 2022, 40, e18807-e18807.	1.6	0
22	Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer. Clinical Breast Cancer, 2021, 21, 292-301.	2.4	4
23	A randomized, openâ€label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced softâ€tissue sarcoma. Cancer, 2021, 127, 894-904.	4.1	12
24	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clinical Cancer Research, 2021, 27, 2424-2429.	7.0	35
25	Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Nonâ€Small Cell Lung Cancer: Real-World Analysis of Select ASCO- <i>Friends</i> Recommendations. Clinical Cancer Research, 2021, 27, 2430-2434.	7.0	28
26	Identification of Transgender People With Cancer in Electronic Health Records: Recommendations Based on CancerLinQ Observations. JCO Oncology Practice, 2021, 17, e336-e342.	2.9	7
27	A Bayesian Phase I/II Design for Cancer Clinical Trials Combining an Immunotherapeutic Agent with a Chemotherapeutic Agent. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 1210-1229.	1.0	3
28	Challenges and opportunities to developing a frailty index using electronic health record data. Journal of Geriatric Oncology, 2021, 12, 851-854.	1.0	7
29	Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. JCO Oncology Practice, 2021, 17, e999-e1011.	2.9	3
30	Abstract CT173: Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) with FGFR1 mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. , 2021, , .		2
31	A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clinical Cancer Research, 2021, 27, 5472-5481.	7.0	4
32	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal of Clinical Oncology, 2021, 39, 2720-2731.	1.6	52
33	Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology, 2021, 39, 2443-2451.	1.6	97
34	Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Reports Medicine, 2021, 2, 100426.	6.5	28
35	Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. Journal of Clinical Oncology, 2020, 38, 480-487.	1.6	3
36	Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology, 2020, 15, 743-750.	3.6	25

#	ARTICLE	IF	CITATIONS
37	Development and implementation of the SUM breast cancer cell line functional genomics knowledge base. <i>Npj Breast Cancer</i> , 2020, 6, 30.	5.2	4
38	Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Targeted Oncology</i> , 2020, 15, 733-741.	3.6	25
39	To Treat or Not to Treat—Balancing Benefits and Risks of Treatment Delay Among Patients With Cancer During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1868.	7.1	6
40	Palbociclib in Patients With Non—Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2020, 4, 757-766.	3.0	52
41	Geographically distributed data should be analyzed with spatial epidemiologic methods. <i>Cancer</i> , 2020, 126, 1161-1162.	4.1	1
42	Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab. <i>Clinical Cancer Research</i> , 2020, 26, 3280-3286.	7.0	28
43	Nicotine replacement therapy sampling for smoking cessation within primary care: results from a pragmatic cluster randomized clinical trial. <i>Addiction</i> , 2020, 115, 1358-1367.	3.3	31
44	Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4637-4637.	1.6	9
45	Vital status ascertainment in cancerlinq discovery (CLQD): Improvement in mortality capture with a supplemental data source.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7064-7064.	1.6	3
46	Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with <i>BRAF</i> V600E mutations: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 122-122.	1.6	10
47	Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with <i>ERBB2</i> amplification or overexpression: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 132-132.	1.6	38
48	Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 133-133.	1.6	28
49	Annual trends in opioid prescribing for patients (Pts) with metastatic non-small cell lung cancer (mNSCLC): Cancerlinq data analysis, 2010 to 2017.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2076-2076.	1.6	0
50	Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5567-5567.	1.6	2
51	Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19311-e19311.	1.6	1
52	NGS testing use and results: A survey of U.S. oncologists.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19145-e19145.	1.6	1
53	Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19046-e19046.	1.6	0
54	Biosimilar usage in practices within the ASCO PracticeNET learning network.. <i>Journal of Clinical Oncology</i> , 2020, 38, 77-77.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Molecular properties of gp100-reactive T cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 68-78.	3.3	9
56	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , 2019, 37, 336-349.	1.6	101
57	Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer. <i>JAMA Network Open</i> , 2019, 2, e191703.	5.9	47
58	Delivery of TRAIL-expressing plasmid DNA to cancer cells <i>in vitro</i> and <i>in vivo</i> using aminoglycoside-derived polymers. <i>Journal of Materials Chemistry B</i> , 2019, 7, 7014-7025.	5.8	11
59	Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors. <i>Journal of Oncology Practice</i> , 2019, 15, e1050-e1065.	2.5	3
60	Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	3.0	46
61	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 118-128.	6.3	49
62	Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 559-571.	2.5	36
63	Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1014-1014.	1.6	29
64	Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9041-9041.	1.6	7
65	Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA108-LBA108.	1.6	10
66	Utilizing visualization to qualitatively evaluate electronic health record-derived database limitations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 317-317.	1.6	1
67	Hypertension and use of bevacizumab among patients treated in community settings.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18279-e18279.	1.6	0
68	Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11008-11008.	1.6	0
69	Effectiveness of ASCO's adverse event reporting decision aid: Results from an interventional study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3065-3065.	1.6	0
70	Visualizing treatment patterns and survival in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 316-316.	1.6	1
71	Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. <i>Cancer Research</i> , 2018, 78, 3067-3074.	0.9	6
72	ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 694-704.	10.7	310

#	ARTICLE	IF	CITATIONS
73	N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 691-702.	4.2	30
74	Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells. <i>Molecular Therapy</i> , 2018, 26, 996-1007.	8.2	8
75	Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis. <i>Scientific Reports</i> , 2018, 8, 1627.	3.3	28
76	TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence. <i>Journal of Leukocyte Biology</i> , 2018, 103, 973-983.	3.3	9
77	Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 146-150.	0.9	5
78	A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2018, 94, 329-339.	1.9	36
79	Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 311-325.	4.2	40
80	CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. <i>Cell Metabolism</i> , 2018, 27, 85-100.e8.	16.2	197
81	Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	3.0	98
82	The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. <i>Journal of Oncology Practice</i> , 2018, 14, e412-e420.	2.5	114
83	Understanding the Role of Advanced Practice Providers in Oncology in the United States. <i>Journal of Oncology Practice</i> , 2018, 14, e518-e532.	2.5	48
84	State Tobacco Policies as Predictors of Evidence-Based Cessation Method Usage: Results From a Large, Nationally Representative Dataset. <i>Nicotine and Tobacco Research</i> , 2018, 20, 1336-1343.	2.6	10
85	Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models. <i>BMC Cancer</i> , 2018, 18, 1233.	2.6	7
86	The effect of bone marrow graft composition on pediatric bone marrow transplantation outcomes. <i>Pediatric Transplantation</i> , 2018, 22, e13287.	1.0	2
87	The Evolution of Phase I Trials, Past, Present, and Future. , 2018, , 17-32.		1
88	An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2018, 10, 185-195.	0.8	11
89	Preoperative predictors of occult nodal disease in cT1N0 oral cavity squamous cell carcinoma: Review of 2623 cases. <i>Head and Neck</i> , 2018, 40, 1967-1976.	2.0	22
90	Nicotine replacement therapy sampling via primary care: Methods from a pragmatic cluster randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2018, 72, 1-7.	1.8	14

#	ARTICLE	IF	CITATIONS
91	Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2532.	1.6	27
92	Attributable failure and costs associated with continued smoking by cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1559-1559.	1.6	0
93	Understanding the Role of Advanced Practice Providers in Oncology in the United States. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 585-598.	0.4	7
94	Adherence to National Comprehensive Cancer Network guidelines for time to initiation of postoperative radiation therapy for patients with head and neck cancer. <i>Cancer</i> , 2017, 123, 2651-2660.	4.1	83
95	Effect of postoperative radiotherapy on survival for surgically managed pT3N0 and pT4aN0 laryngeal cancer: Analysis of the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 2248-2257.	4.1	17
96	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 82.	17.0	105
97	CD8, FoxP3, and CD45RO+ Lymphocytic Infiltrates in Type I and Type II Endometrial Cancers in African American and European American Females. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 540-549.	1.4	5
98	A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4642-4650.	7.0	124
99	Platelets subvert T cell immunity against cancer via GARP-TGF β axis. <i>Science Immunology</i> , 2017, 2, .	11.9	237
100	Snus undermines quit attempts but not abstinence: a randomised clinical trial among US smokers. <i>Tobacco Control</i> , 2017, 26, 202-209.	3.2	15
101	Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 63-75.	4.2	4
102	Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1411-1424.	4.2	15
103	HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer. <i>Molecular Therapy - Oncolytics</i> , 2017, 5, 105-115.	4.4	17
104	Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 737-751.	4.2	7
105	The differential impact of state tobacco control policies on cessation treatment utilization across established tobacco disparities groups. <i>Preventive Medicine</i> , 2017, 105, 319-325.	3.4	5
106	Bone mineral density during pregnancy in women participating in a randomized controlled trial of vitamin D supplementation. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 1422-1430.	4.7	18
107	Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer. <i>Cancer</i> , 2017, 123, 4841-4850.	4.1	107
108	Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis. <i>Scientific Reports</i> , 2017, 7, 15552.	3.3	24

#	ARTICLE	IF	CITATIONS
109	Smoking status and symptom burden in surgical head and neck cancer patients. <i>Laryngoscope</i> , 2017, 127, 127-133.	2.0	28
110	Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 751-758.	1.6	110
111	Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2017, 35, 3737-3744.	1.6	331
112	The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer. <i>Oncotarget</i> , 2017, 8, 22991-23007.	1.8	24
113	Abstract A50: An exploratory study examining the acute phase impact of resection on biological and psychological markers of stress among early stage non-small cell lung cancer patients. , 2017, , .		0
114	Defining adverse events of anti-programmed-death-1 (Anti-PD1) agents using FDA adverse event reporting system (FAERS).. <i>Journal of Clinical Oncology</i> , 2017, 35, e14568-e14568.	1.6	0
115	Abstract 5474: Sphingosine kinase 2/sphingosine 1-phosphate signaling regulates p16 mediated accelerated aging in normal somatic tissues and tcf21 mediated tumor suppression in lung cancer. , 2017, , .		0
116	Surface Expression of TGF β 2 Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer. <i>Cancer Research</i> , 2016, 76, 7106-7117.	0.9	76
117	Relationship of ABO Incompatible HSCT to Outcomes in Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S247.	2.0	0
118	Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. <i>Journal of Leukocyte Biology</i> , 2016, 100, 545-557.	3.3	15
119	Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. <i>Cancer Research</i> , 2016, 76, 6006-6016.	0.9	56
120	Association of <i>BRCA1</i> Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 337-343.	1.3	53
121	A longitudinal, naturalistic study of U.S. smokers' trial and adoption of snus. <i>Addictive Behaviors</i> , 2016, 63, 82-88.	3.0	8
122	One-Year Smoking Trajectories Among Established Adult Smokers With Low Baseline Motivation to Quit. <i>Nicotine and Tobacco Research</i> , 2016, 20, ntw264.	2.6	5
123	Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases?. <i>Gynecologic Oncology</i> , 2016, 142, 278-282.	1.4	18
124	The Effect of Bone Marrow Graft Composition on Pediatric Bone Marrow Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S247-S248.	2.0	0
125	TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 293-304.	4.2	41
126	Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control. <i>Oncotarget</i> , 2016, 7, 69371-69383.	1.8	10

#	ARTICLE	IF	CITATIONS
127	Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. <i>Oncotarget</i> , 2016, 7, 36138-36153.	1.8	6
128	Reduction in promotor methylation utilizing EGCG (epigallocatechin-3-gallate) restores RXR α expression in human colon cancer cells. <i>Oncotarget</i> , 2016, 7, 35313-35326.	1.8	53
129	A feasibility and safety study of vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14579-e14579.	1.6	0
130	Evaluating the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in a predominantly African American sample. <i>SpringerPlus</i> , 2015, 4, 411.	1.2	4
131	A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs. <i>Clinical Trials</i> , 2015, 12, 24-33.	1.6	5
132	Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation. <i>Science Signaling</i> , 2015, 8, ra58.	3.6	114
133	The Faculty Costs to Educate a Biomedical Sciences Graduate Student. <i>CBE Life Sciences Education</i> , 2015, 14, ar3.	2.3	4
134	The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2744-2752.	4.1	82
135	IL-2 α mediates temporal regulation of IL-2 signaling and enhances immunotherapy. <i>Science Translational Medicine</i> , 2015, 7, 311ra170.	12.4	49
136	Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner. <i>Journal of Biological Chemistry</i> , 2015, 290, 13157-13167.	3.4	31
137	Effector CD8 ⁺ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7R α Dependent. <i>Cancer Immunology Research</i> , 2015, 3, 1364-1374.	3.4	26
138	Oncogenic signaling in amphiregulin and EGFR α -expressing PTEN α -null human breast cancer. <i>Molecular Oncology</i> , 2015, 9, 527-543.	4.6	24
139	Cervical esophageal cancer: A population α -based study. <i>Head and Neck</i> , 2015, 37, 808-814.	2.0	59
140	Abstract CT122: RCT of an herbal mouthrinse for radiotherapy induced oral mucositis in cancer patients. , 2015, , .		0
141	Incorporating Patient Satisfaction Metrics in Assessing Multidisciplinary Breast Cancer Care Quality. <i>Southern Medical Journal</i> , 2015, 108, 372-6.	0.7	7
142	KAT6A, a Chromatin Modifier from the 8p11-p12 Amplicon is a Candidate Oncogene in Luminal Breast Cancer. <i>Neoplasia</i> , 2014, 16, 644-655.	5.3	37
143	Affective Motives for Smoking Among Early Stage Smokers. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1387-1393.	2.6	11
144	A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF α -Secreting Breast Tumor Vaccine for HER2 ⁺ Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 949-961.	3.4	77

#	ARTICLE	IF	CITATIONS
145	Promoting Thiol Expression Increases the Durability of Antitumor T-cell Functions. <i>Cancer Research</i> , 2014, 74, 6036-6047.	0.9	34
146	Dynamics of tissue shrinkage during ablative temperature exposures. <i>Physiological Measurement</i> , 2014, 35, 55-67.	2.1	69
147	Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer. <i>Journal of Controlled Release</i> , 2014, 176, 35-43.	9.9	20
148	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 1277-1280.	1.6	354
149	Phase 2 Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 837-844.	0.8	45
150	SPECT Analysis of Cardiac Perfusion Changes After Whole-Breast/Chest Wall Radiation Therapy With or Without Active Breathing Coordinator: Results of a Randomized Phase 3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 778-785.	0.8	70
151	Regulation of the Tumor Suppressor FOXO3 by the Thromboxane-A2 Receptors in Urothelial Cancer. <i>PLoS ONE</i> , 2014, 9, e107530.	2.5	14
152	Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. <i>Oncoscience</i> , 2014, 1, 522-528.	2.2	24
153	Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A α ERIPK1 α -dependent necroptosis. <i>EMBO Molecular Medicine</i> , 2013, 5, 105-121.	6.9	217
154	Mutant HSP70 Reverses Autoimmune Depigmentation in Vitiligo. <i>Science Translational Medicine</i> , 2013, 5, 174ra28.	12.4	100
155	Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. <i>Haematologica</i> , 2012, 97, 1736-1742.	3.5	65
156	Vitamin D3 supplementation (4000 IU/d for 1 y) eliminates differences in circulating 25-hydroxyvitamin D between African American and white men. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 332-336.	4.7	28
157	Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method. <i>Clinical Trials</i> , 2012, 9, 303-313.	1.6	37
158	A Coreceptor-Independent Transgenic Human TCR Mediates Anti-Tumor and Anti-Self Immunity in Mice. <i>Journal of Immunology</i> , 2012, 189, 1627-1638.	0.8	44
159	Vitamin D ³ Supplementation at 4000 International Units Per Day for One Year Results in a Decrease of Positive Cores at Repeat Biopsy in Subjects with Low-Risk Prostate Cancer under Active Surveillance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2315-2324.	3.6	112
160	Latent Class Analysis. , 2012, , 700-707.		0
161	ZEB1-responsive genes in non-small cell lung cancer. <i>Cancer Letters</i> , 2011, 300, 66-78.	7.2	147
162	A Novel Extracellular Hsp90 Mediated Co-Receptor Function for LRP1 Regulates EphA2 Dependent Glioblastoma Cell Invasion. <i>PLoS ONE</i> , 2011, 6, e17649.	2.5	113

#	ARTICLE	IF	CITATIONS
163	Using Endobronchial Ultrasound Features to Predict Lymph Node Metastasis in Patients With Lung Cancer. <i>Chest</i> , 2011, 140, 1550-1556.	0.8	91
164	Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading. <i>Statistics in Medicine</i> , 2011, 30, 2070-2080.	1.6	43
165	Incorporating scientific knowledge into phenotype development: Penalized latent class regression. <i>Statistics in Medicine</i> , 2011, 30, 784-798.	1.6	4
166	Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , 2010, 16, 1726-1736.	7.0	152
167	K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2010, 16, 338-347.	7.0	106
168	Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 203-211.	7.0	186
169	Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) With Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML). <i>Blood</i> , 2010, 116, 186-186.	1.4	2
170	Adolescent nondaily smokers: Favorable views of tobacco yet receptive to cessation. <i>Nicotine and Tobacco Research</i> , 2009, 11, 348-355.	2.6	24
171	Modified test statistics by inter-voxel variance shrinkage with an application to f MRI. <i>Biostatistics</i> , 2009, 10, 219-227.	1.5	10
172	Dose-finding study of ¹⁵³ Sm-EDTMP in patients with poor-prognosis osteosarcoma. <i>Cancer</i> , 2009, 115, 2514-2522.	4.1	55
173	Repeatable battery for assessment of neuropsychological status in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1453-1460.	3.9	20
174	Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 49-59.	4.2	1,089
175	Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. <i>Blood</i> , 2009, 113, 4841-4852.	1.4	54
176	Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 97-107.	7.0	163
177	Effect of DNA Methylation on Identification of Aggressive Prostate Cancer. <i>Urology</i> , 2008, 72, 1234-1239.	1.0	46
178	Tamoxifen-stimulated growth of breast cancer due to p21 loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 288-293.	7.1	86
179	Pharmacodynamic-Guided Modified Continuous Reassessment Method-Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 4172-4179.	1.6	63
180	Novel Role of Thromboxane Receptors β^2 Isoform in Bladder Cancer Pathogenesis. <i>Cancer Research</i> , 2008, 68, 4097-4104.	0.9	60

#	ARTICLE	IF	CITATIONS
181	Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. <i>Anti-Cancer Drugs</i> , 2008, 19, 1007-1011.	1.4	0
182	How Should Treatment Decisions Be Made for Incapacitated Patients, and Why?. <i>PLoS Medicine</i> , 2007, 4, e35.	8.4	34
183	Social and Communication Development in Toddlers With Early and Later Diagnosis of Autism Spectrum Disorders. <i>Archives of General Psychiatry</i> , 2007, 64, 853.	12.3	453
184	Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3965-3970.	1.6	257
185	A Prostate-Specific Antigen-Activated Channel-Forming Toxin as Therapy for Prostatic Disease. <i>Journal of the National Cancer Institute</i> , 2007, 99, 376-385.	6.3	84
186	Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. <i>Carcinogenesis</i> , 2007, 28, 1485-1490.	2.8	283
187	Cross-study validation and combined analysis of gene expression microarray data. <i>Biostatistics</i> , 2007, 9, 333-354.	1.5	46
188	A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. <i>Blood</i> , 2007, 109, 1387-1394.	1.4	180
189	Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1185-1191.	2.0	24
190	Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. <i>Gynecologic Oncology</i> , 2007, 106, 82-88.	1.4	77
191	Response to Joint Attention in Toddlers at Risk for Autism Spectrum Disorder: A Prospective Study. <i>Journal of Autism and Developmental Disorders</i> , 2007, 37, 37-48.	2.7	205
192	The continual reassessment method for dose-finding studies: a tutorial. <i>Clinical Trials</i> , 2006, 3, 57-71.	1.6	165
193	Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin's Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 965-972.	2.0	44
194	The Accuracy of Surrogate Decision Makers. <i>Archives of Internal Medicine</i> , 2006, 166, 493.	3.8	796
195	Development in infants with autism spectrum disorders: a prospective study. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2006, 47, 629-638.	5.2	569
196	Prevalence and determinants of physician bedside rationing. <i>Journal of General Internal Medicine</i> , 2006, 21, 1138-1143.	2.6	99
197	Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 281-286.	3.4	81
198	Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid. <i>Clinical Cancer Research</i> , 2006, 12, 3306-3310.	7.0	122

#	ARTICLE	IF	CITATIONS
199	Ductal Access for Prevention and Therapy of Mammary Tumors. <i>Cancer Research</i> , 2006, 66, 638-645.	0.9	84
200	Does It Pay to Pay?. <i>Nursing Research</i> , 2005, 54, 178-183.	1.7	51
201	Pharmacologic and Toxicologic Evaluation of <i>C. novyi</i> -NT Spores. <i>Toxicological Sciences</i> , 2005, 88, 562-575.	3.1	90
202	Very High Frequency of Hypermethylated Genes in Breast Cancer Metastasis to the Bone, Brain, and Lung. <i>Clinical Cancer Research</i> , 2004, 10, 3104-3109.	7.0	129
203	Gene expression alterations over large chromosomal regions in cancers include multiple genes unrelated to malignant progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8715-8720.	7.1	49
204	Response to letters on B-readers study. <i>Academic Radiology</i> , 2004, 11, 1402-1404.	2.5	0
205	Comparison of B-readers' interpretations of chest radiographs for asbestos related changes. <i>Academic Radiology</i> , 2004, 11, 843-856.	2.5	39
206	Eliminating catheter-related bloodstream infections in the intensive care unit*. <i>Critical Care Medicine</i> , 2004, 32, 2014-2020.	0.9	996
207	Models for Probability of Under- and Overexpression: The POE Scale. , 0, , 137-154.		2